(BSGM) Update: Today’s Nasdaq Biotech Idea Surges Approximately 12% Out Of The Opening Bell (Read Now)

StockWireNews

(BSGM) Update: Today's Nasdaq Biotech Idea Surges Approximately 12% Out Of The Opening Bell (Read Now)

Report: $13 Analyst Target From Laidlaw & Company

November 16th

Good Morning,

BSGM comes out firing this morning and is making major moves.

Up approximately 12% early, this Nasdaq biotech may enter beast mode any second. Here's why.

At this moment it is trading above 4 key lines of potential support in its:

5-Day Exponential Moving Average (EMA)
13-Day EMA
50-Day Simple Moving Average (SMA)
200-Day SMA

Plus, hitting $3.70 early, BSGM is now trading at levels that it hasn't risen to since July of this year.

Could more be on the way?

With a handful of key press releases since the beginning of November highlighting their #1 product being used in several major hospitals in the U.S., the company looks to be expanding at quite the pace.

If you haven't read my initial report yet, do so now and get BSGM on your radar quickly today.

-----

Hold on for a second... My head is still spinning.

We've been on quite the roll the last few weeks with some serious breakout champs, but that was all put to shame with what happened on Friday.

My last stunner that flipped the market on its head was STAL.

Opening at $.75, it ran like an untamed beast all the way to $6.40.

From an intraday standpoint, STAL turned in a crazy move of 753%.

Yes. You read that correctly. 753%.

And I thought I wouldn't be able to top XCPL from just over 2 weeks ago that ran approximately 554% intraday (approx. 860% over 2 days).

So what do I have up my sleeve next? Well... Here it is.

For Tuesday, November 16th, there is only one Nasdaq biotech profile to have on your radar:

*BioSig Technologies, Inc. (BSGM)*

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

A Potentially Game-Changing Product

As mentioned above, BioSig’s PURE EP device is a computerized system designed to reveal the full range of cardiac signals. All while providing physicians with signal clarity during procedures performed to address cardiac arrhythmias.

It aims to fill a significant need by:(1)

Improving Signal Clarity Through Reduction of ‘Noise’ and Artifacts
Minimizing Need for Repeat Procedures
Preserving Important Clinical Information
Shortening Procedure Times
Increasing Confidence in Performing Complex Ablations
Offering a customizable user control interface for a better understanding of ECG and intracardiac signals

-----

And right now, this profile has several potential catalysts that could fuel a vertical move in the near term. Here's what you need to know...

No. 1 BSGM Potential Catalyst - Analyst Provides $13 Price Target

Laidlaw & Company analyst, Yale Jen, reiterated a "Buy" designation last month along with a $13 price target on BSGM.

Here a key highlight from his report:

Action. With the PURE EP system at an early stage of commercialization and a positive outlook for its revenue stream, we believe BSGM shares remain undervalued. We reiterate our Buy rating and 12-month target price of $13 based on our forward P/E analysis.

-----

No. 2 BSGM Potential Catalyst - Company Expands Footprint In Multiple New Locations

In the last two weeks, BSGM has expanded its PURE EP System footprint in multiple locations. Here are some key details

BioSig Adds To Its Clinical Footprint In Texas

The Company’s signal processing technology for arrhythmia care is being installed in a highly ranked hospital in Dallas

Westport, CT, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), [...], today announced that it is installing a PURE EP™ System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company’s 17th installation and its fifth in Texas, the state with some of the most extensive clinical programs focused on arrhythmia care in the country.

[...]

Read the full article here.

BioSig Installs its Signal Processing Technology for Arrhythmia Care at a Leading Hospital in Boston

Latest installation follows a steady rise in patient cases conducted with the PURE EP™ System

Westport, CT, Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), [..], today announced that it is installing a PURE EP™ System for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA. This new evaluation agreement brings the Company up to 16 installed centers. Procedural cases are expected to commence in early December at this renowned medical center.

[...]

Read the full article here.

BioSig Expands its Installation Base in Texas

Signs a new installation agreement with high-volume center in San Antonio

Westport, CT, Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), [...], today announced the Company is installing a PURE EP(tm) System for an evaluation at the Methodist Hospital in San Antonio, TX, one of the largest hospitals in the United States in terms of the number of available beds. This 90-day evaluation agreement brings the Company up to 15 installed centers.

[...]

Read the full article here.

-----

No. 3 BSGM Potential Catalyst - Publishing Of Positive Clinical Data

Clinical Data Published in the Journal of Cardiovascular Electrophysiology Could Be Important for This St-ock

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a fin-an-cial partner of Benzinga.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced that an article titled "Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study" has been published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access as of September 23, 2021, via the Wiley Online Library.

[...]

Read the full article here.

-----

No. 4 BSGM Potential Catalyst - Major Manufacturing Deal Reached With Global Leader

BioSig Inks Manufacturing Deal with Plexus Corp

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a fin-an-cial partner of Benzinga.

With the recent successes of its PURE EP™ system underway, BioSig Technologies Inc. (NASDAQ: BSGM) has continued its trend of growth and innovation.

Thanks to a manufacturing and professional services agreement with Plexus Corp. (NASDAQ: PLXS), a global leader in complex product design, PURE EP will be brought to market in one of the company’s largest market sectors: healthcare and life sciences. Ultimately, these two industries bring an enormous amount of revenue to Plexus, and BioSig’s product will increase this even further.

[...]

Plexus plans on providing 1st-class infrastructure for this PURE EP system, increasing the supply, and ultimately supporting BioSig’s mission to advance therapies through technological innovation. This market sector represents about 40 percent of annual revenue for Plexus, proving its viability and growth potential.

In addition, Plexus is developing a product pipeline for NeuroClear Technologies, a subsidiary of BioSig. NeuroClear Technologies aims to address additional issues within the realm of bioelectronic medicine, including nerve stimulation used to treat cognitive disorders and nephrology.

[...]

Read the full article here.

-----

No. 5 BSGM Potential Catalyst - Trading Above Key Lines And Building Moment Recently

Take a look at the BSGM 2-month chart:

As of close on Monday, BSGM was trading above multiple lines of potential support after a recent hot streak.

Those lines include BSGM's:

5-Day Exponential Moving Average (EMA)
13-Day EMA
20-Day Simple Moving Average (SMA)
50-Day SMA
100-Day SMA

If potential support starts building at those levels, it could provide the building blocks for this profile to try and run down previous highs.

And with a 52-week high of $6.14 (not to mention its $13 P.T. from Laidlaw & Company), this profile is displaying a ton of upside potential from its closing valuation Monday.

Now, I'm not saying BSGM is soaring to either of those levels today, but it's noteworthy to know the potential upside this Nasdaq biotech idea has from current levels.

-----

BSGM Recap: 5 Potential Catalysts To Know Now

No. 1 - Analyst Provides $13 Price Target

No. 2 - Company Expands Footprint In Multiple New Locations

No. 3 - Publishing Of Positive Clinical Data

No. 4 - Major Manufacturing Deal Reached With Global Leader

No. 5 - Trading Above Key Lines And Building Moment Recently

-----

Coverage is initiated on BSGM. When you have a second later, do this:

If there are any more updates today, I'll get them out to you quickly.

Sincerely,

Kai Parker

StockWireNews

Source 1
Source 2

Company Website

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 2/19/20 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-five thousand USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been paid an additional five thousand USD via bank wire transfer on 2/21/20 for continuing coverage of (BSGM). We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 4/9/20 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid seven thousand USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 6/17/20 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a one day period on 1/13/21 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/30/21 and ending on 7/1/21 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-six thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 11/16/21 and ending on 11/17/21 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). To date, we have been compensated a total of one hundred and forty-six thousand USD to disseminate information about (BSGM). We have not been compensated for our profile on (STAL). We own zero shares of (STAL). We have not been compensated for our profile on (XCPL). We own zero shares of (XCPL).